Tranform lives around the world.
Your 2019 contribution can help end this disease.
Give the Gift of Hope

“Simply the Best” Dinner and Gala Honors Those Working to Fight Lung Cancer

2019-11-14T14:11:12-06:00November 14th, 2019|Hot Topics|

AstraZeneca Announced as 2019 "Simply the Best Award" Honoree SAN CARLOS, Calif. and WASHINGTON DC, November 12, 2019 – GO2 Foundation for Lung Cancer (a merger of the Bonnie J. Addario Lung Cancer Foundation and Lung Cancer Alliance) recognized AstraZeneca on November 9 at its 14th annual "Simply the Best" Dinner. AstraZeneca was honored with the “Simply the Best Award” for its continued dedication to research and development of new lung cancer treatments.GO2 Foundation’s annual event is a celebration of survivors, [...]

Survey Shows That Despite Gains, Stigma Remains a Problem

2018-09-07T16:42:32-06:00September 5th, 2018|Hot Topics, News|

SURVEY SHOWS INCREASED PUBLIC AWARENESS OF LUNG CANCER OVER LAST DECADE Despite Gains, Stigma Remains a Problem; Survivors Continue to Shoulder Blame for Diagnosis Wednesday, September 5, 2018 – Survey results released today by Lung Cancer Alliance (LCA) show that general awareness about lung cancer has improved significantly over the last decade with 94 percent of the public reporting familiarity with lung cancer. Despite this change in overall perspective, findings also indicate that lung cancer stigma remains a significant problem with an [...]

FDA Approves Tagrisso as First-line Treatment for NSCLC

2018-04-23T13:55:25-06:00April 19th, 2018|Hot Topics, News|

Thursday, April 19, 2018 – This week the Food and Drug Administration (FDA) approved targeted therapy drug, osimertinib (Tagrisso), as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors with the EGFR mutations. The approval is based off results from a study showing that Tagrisso as a first-line treatment prevented the cancer from progressing for 8.7 months longer than erlotinib (Tarceva) and gefitinib (Iressa). Up until this point, Tagrisso was approved as a second-line treatment [...]